Crossmark

Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose

Crossref DOI link: https://doi.org/10.1007/s12185-022-03380-2

Published Online: 2022-05-27

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Komatsu, Norio https://orcid.org/0000-0003-1880-9126
Hashimoto, Yoshinori

Baba, Terumi

Otsuka, Manami

Akimoto, Takafumi

Fernandez, Jovelle
Funding

Funding for this research was provided by:

Takeda Pharmaceutical Company Limited
License Information

Text and Data Mining valid from 2022-05-27

Version of Record valid from 2022-05-27
More Information

Article History

Received: 14 December 2021

Revised: 26 April 2022

Accepted: 27 April 2022

First Online: 27 May 2022

Declarations

:

: NK is a board member of PharmaEssentia Japan. NK received personal fees from Novartis, PharmaEssentia, AbbVie, Celgene, Japan Tobacco International, and Otsuka, and grants from Takeda/Shire, Novartis, FUJIFILM Wako Pure Chemical Corporation, Fuso Pharmaceutical, Pfizer, Perseus Proteomics, Otsuka, Chugai, Kyowa Kirin, Sumitomo Dainippon Pharma, and Bristol-Myers Squibb. NK and YH received personal fees from Takeda/Shire. NK and YH received grants from Meiji Seika Pharma and PharmaEssentia Japan. TB is an employee of Takeda/Shire and is a student in the Department of Hematology, Juntendo University Graduate School of Medicine. MO and TA are employees of Takeda/Shire. JF is an employee of Takeda and owns restricted stocks in GSK and Takeda.

Document is current

Any future updates will be listed below